Mesenchymal stem cells harvested from your own bone marrow and fat tissue, delivering biological signaling molecules that modulate inflammation and support tissue healing at the molecular level.
The traditional understanding of stem cell therapy focused on differentiation—the idea that injected stem cells would transform into disc cells, cartilage cells, or bone cells to replace damaged tissue. While differentiation may occur, recent research suggests that the paracrine effect may be equally or more important. MSCs secrete a rich array of bioactive molecules that shape the local tissue environment.
Mesenchymal stem cells (MSCs) work through multiple mechanisms:
Cells may help shift the tissue environment from degenerative toward regenerative. This paracrine understanding has transformed how we think about cellular therapy. The cells are not just building blocks—they are signaling factories that help shift the local biological environment where damaged tissue needs support.
Bone marrow aspirate concentrate (BMAC) provides a concentrated source of MSCs along with hematopoietic progenitors, growth factors, and anti-inflammatory cytokines. BMAC-derived MSCs have osteogenic and chondrogenic differentiation potential, making them a candidate for use in disc, cartilage, and bone healing applications.
Adipose-derived mesenchymal stem cells are harvested from the patient's own fat tissue via a minimally invasive lipoaspirate procedure. Adipose tissue contains a high density of MSCs—often 100 to 500 times more MSCs per volume than bone marrow. Adipose-derived MSCs excel at anti-inflammatory paracrine signaling and immunomodulation, and they show strong capacity for soft tissue repair.
In my practice, I often combine both autologous sources in a single treatment session. BMAC provides the osteogenic and chondrogenic machinery for disc and joint repair, while adipose-derived MSCs amplify the anti-inflammatory and immunomodulatory signaling. This combination approach—using your body's two richest autologous stem cell reservoirs together—is a key differentiator of our practice and one of the most comprehensive autologous biological approaches we offer for spinal degeneration.
One of the most exciting developments in regenerative medicine is the recognition that exosomes—nanoscale vesicles secreted by MSCs—may mediate much of cellular therapy's therapeutic effect. Exosomes carry microRNA, proteins, and lipids that modulate gene expression and cellular behavior in target tissues. This suggests that the future of cellular therapy may involve not just delivering cells, but harnessing and optimizing the signaling molecules those cells produce.
Understanding this relationship informs how I use cellular therapy today. When I deliver BMAC to a degenerating disc, I am not simply providing cells—I am providing a complex biological package that includes cells, growth factors, cytokines, and exosomes working in concert. This integrated approach is what we believe gives cellular therapy its potential advantage over growth factors alone.
Regenerative cellular therapy is appropriate for advanced degenerative conditions where PRP alone provides insufficient biological stimulus. These include:
Cellular therapy harnesses your body's own healing cells to shift the tissue environment from degenerative toward regenerative. Let's discuss whether this approach is appropriate for your condition.